Featuring an interview with Dr Rana R McKay, including the following topics:

• Prostate Cancer Working Group (PCWG4) revised terminology (0:00)
• Cardiovascular effects associated with GnRH agonists versus antagonists; mechanism of action (2:17)
• Combination therapy using relugolix; factors affecting persistence and adherence to GnRH agents (12:06)
• Takeaways from the Phase III EMBARK study (19:36)
• Use of CAR (chimeric antigen receptor) T-cell therapy and T-cell engagers (27:20)
• Potential role of circulating tumor DNA minimal residual disease testing; use of olaparib/radium-223 (29:24)

CME information and select publications

Featuring perspectives from Dr Alexandra Drakaki, Ms Krisztina Emodi, Dr Terence Friedlander and Ms Margarita Huober, moderated by Dr Friedlander, including the following topics:

• Introduction: Basic Biology of Nonmetastatic Urothelial Bladder Cancer (UBC) (0:00)
• Systemic Therapy for Cisplatin-Eligible Patients with Muscle-Invasive Bladder Cancer (MIBC) (13:35)
• Evolving Approach to Systemic Therapy for Cisplatin-Ineligible Patients with MIBC (37:13)
• Immune Checkpoint Inhibitors in Non-Muscle-Invasive Bladder Cancer (58:55)
• Novel Intravesical Therapies for Nonmetastatic UBC (1:10:20)

NCPD information and select publications

Featuring perspectives from Dr Lyudmila Bazhenova and Dr Corey J Langer, including the following topics:

• Introduction (0:00)
• Therapeutic Approaches Targeting HER2 and RET — Dr Bazhenova (9:09)
• Therapeutic Approaches Targeting ALK and ROS1 — Dr Langer (31:56)

CME information and select publications